Method for treating cancer patients
AssigneePasKen Products Co., Ltd.
InventorTsunataro Kishida
Life of this patent
Estimating the term…
Abstract
A new immunotherapy to cancer patients is provided. In the therapy, lymphocytes collected from a patient by leukopheresis are treated with interferon-.alpha. in vitro for a short period of term and then returned to the patient intravenously. According to the therapy, reduction in sensitivity of tumor cells to natural killer-cell lysis due to administration of interferon-.alpha. is eliminated, the activities of NK cell and 2-5AS and interferon-producing capacity can be enhanced, a large amount of lymphocytes can be activated directly in vitro with the dose of optimally adjusted to the patient, none of side effects are found, and any other potentiators and comodulaators, which may not be allowed to use in vivo, can be added to the lymphocytes and removed therefrom before returning to the patient.
Claims21
A method for treating a patient with cancer, which comprises collecting lymphocytes from the patient by leukopheresis, contacting the lymphocytes with interferon-.alpha. in vitro for a term effective to potentiate the immunological activity of the lymphocytes, and then returning the lymphocytes to the patient intravenously.
A method for treating a patient with cancer, which comprises collecting lymphocytes from the patient by leukopheresis, contacting in vitro, the lymphocytes with interferon-alpha in an amount which is effective to potentiate the immunological activity of the lymphocytes when administered to the patient for a short term, and then returning, intravenously, the lymphocytes together with the interferon-alpha to the patient.
A method for potentiating lymphocytes which comprises collecting lymphocytes from a patient by leukopheresis, contacting the collected lymphocytes with interferon-alpha in an amount which is effective to potentiate the immunological activity of the lymphocytes when administered to the patient in vitro for a short term effective to potentiate the immunological activity of the lymphocytes, and returning the treated lymphocytes to the patient.
Dependencies are inferred from the claim text.